U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product, By Region, And Segment Forecasts, 2026 - 2033

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
  • 1.4.6. Research Assumption
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. Objectives
  • 1.8.1. Objective - 1
  • 1.8.2. Objective - 2
  • 1.8.3. Objective - 3
• 1.9. List of Secondary Sources
• 1.10. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. U.S. Contraceptive Market
  • 2.1.1. Market Snapshot
  • 2.1.2. Segment Snapshot
    • 2.1.2.1. Product segment outlook
  • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Regulatory Framework
• 3.5. Business Environment Analysis Tools
  • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis

Chapter 4. Product Business Analysis

• 4.1. U.S. Contraceptive Market: Product Movement Analysis
• 4.2. U.S. Contraceptive Market: Product Segment Dashboard
• 4.3. Product Movement & Market Share Analysis, 2024 & 2033
• 4.4. U.S. Contraceptive Market Estimates & Forecast, by Product
• 4.5. Pills
  • 4.5.1. Pills Market, 2021 - 2033 (USD Million)
• 4.6. Intrauterine Devices (IUD)
  • 4.6.1. Intrauterine Devices (IUD) Market, 2021 - 2033 (USD Million)
  • 4.6.2. Hormonal IUD
    • 4.6.2.1. Hormonal IUD market, 2021 - 2033 (USD Million)
  • 4.6.3. Nonhormonal IUD
    • 4.6.3.1. Nonhormonal IUD market, 2021 - 2033 (USD Million)
• 4.7. Condoms
  • 4.7.1. Condoms Market, 2021 - 2033 (USD Million)
  • 4.7.2. Male Condoms
    • 4.7.2.1. Male condoms market, 2021 - 2033 (USD Million)
  • 4.7.3. Female Condoms
    • 4.7.3.1. Female condoms market, 2021 - 2033 (USD Million)
• 4.8. Vaginal Ring
  • 4.8.1. Vaginal Ring Market, 2021 - 2033 (USD Million)
• 4.9. Subdermal Implants
  • 4.9.1. Subdermal Implants Market, 2021 - 2033 (USD Million)
• 4.10. Injectable
  • 4.10.1. Injectable Market, 2021 - 2033 (USD Million)
• 4.11. Others
  • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Region Business Analysis

• 5.1. U.S. Contraceptive Market: Region Movement Analysis
• 5.2. U.S. Contraceptive Market: Region Segment Dashboard
• 5.3. Region Movement & Market Share Analysis, 2025 & 2033
• 5.4. U.S. Contraceptive Market Estimates & Forecast, by Region
• 5.5. West
  • 5.5.1. West Market, 2021 - 2033 (USD Million)
• 5.6. Southeast
  • 5.6.1. Southeast Market, 2021 - 2033 (USD Million)
• 5.7. Southwest
  • 5.7.1. Southwest Market, 2021 - 2033 (USD Million)
• 5.8. Northeast
  • 5.8.1. Northeast Market, 2021 - 2033 (USD Million)
• 5.9. Midwest
  • 5.9.1. Midwest Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company Categorization
• 6.2. Company Market Position Analysis, 2025
• 6.3. Strategy Mapping
  • 6.3.1. Mergers & Acquisitions
  • 6.3.2. Partnership and Collaborations
  • 6.3.3. New Product Launch
  • 6.3.4. Others
• 6.4. Company Profiles/Listing
  • 6.4.1. Church & Dwight Co., Inc.
    • 6.4.1.1. Overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Product benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Reckitt Benckiser Group Plc
    • 6.4.2.1. Overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Product benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Organon Group of Companies
    • 6.4.3.1. Overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Product benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Pfizer, Inc.
    • 6.4.4.1. Overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Product benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Teva Pharmaceutical Industries Ltd.
    • 6.4.5.1. Overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Product benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. The Cooper Companies, Inc.
    • 6.4.6.1. Overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Product benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Mayer Laboratories Inc
    • 6.4.7.1. Overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Product benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Agile Therapeutics
    • 6.4.8.1. Overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Product benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. Mayne Pharma Group Limited.
    • 6.4.9.1. Overview
    • 6.4.9.2. Financial performance
    • 6.4.9.3. Product benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Bayer AG
    • 6.4.10.1. Overview
    • 6.4.10.2. Financial performance
    • 6.4.10.3. Product benchmarking
    • 6.4.10.4. Strategic initiatives
  • 6.4.11. Afaxys, Inc.
    • 6.4.11.1. Overview
    • 6.4.11.2. Financial performance
    • 6.4.11.3. Product benchmarking
    • 6.4.11.4. Strategic initiatives
  • 6.4.12. AbbVie
    • 6.4.12.1. Overview
    • 6.4.12.2. Financial performance
    • 6.4.12.3. Product benchmarking
    • 6.4.12.4. Strategic initiatives
  • 6.4.13. Gedeon Richter
    • 6.4.13.1. Overview
    • 6.4.13.2. Financial performance
    • 6.4.13.3. Product benchmarking
    • 6.4.13.4. Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Contraceptive methods and associated side effects
• Table 4 Classification of contraceptives by the U.S. FDA
• Table 5 States that have expanded contraceptive coverage guarantee in the Affordable Care Act
• Table 6 Types of oral contraceptives, composition, and regimen
• Table 7 List of intrauterine devices currently available in the U.S.
• Table 8 Types of male condom variants
• Table 9 US contraceptive market revenue estimates and forecast, by product, 2021 - 2033 (USD Million)
• Table 10 US contraceptive market revenue estimates and forecast, by region, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 U.S. contraceptive market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot
• Fig. 11 Competitive landscape
• Fig. 12 U.S. contraceptive market: Parent market outlook
• Fig. 13 U.S. contraceptive market dynamics
• Fig. 14 Market driver relevance analysis (Current & future impact)
• Fig. 15 Market restraint relevance analysis (Current & future impact)
• Fig. 16 U.S. contraceptive market: Porter's five forces analysis
• Fig. 17 U.S. contraceptive market: PESTLE analysis
• Fig. 18 U.S. contraceptive market: product segment dashboard
• Fig. 19 U.S. contraceptive market: product market share analysis, 2024 & 2033
• Fig. 20 Pills market, 2021 - 2033 (USD Million)
• Fig. 21 Intrauterine Devices (IUD) market, 2021 - 2033 (USD Million)
• Fig. 22 Hormonal IUD market, 2021 - 2033 (USD Million)
• Fig. 23 Nonhormonal IUD market, 2021 - 2033 (USD Million)
• Fig. 24 Condoms market, 2021 - 2033 (USD Million)
• Fig. 25 Male condoms market, 2021 - 2033 (USD Million)
• Fig. 26 Female condoms market, 2021 - 2033 (USD Million)
• Fig. 27 Vaginal ring market, 2021 - 2033 (USD Million)
• Fig. 28 Subdermal implants market, 2021 - 2033 (USD Million)
• Fig. 29 Injectable market, 2021 - 2033 (USD Million)
• Fig. 30 Others market, 2021 - 2033 (USD Million)
• Fig. 31 U.S. contraceptive market: Region segment dashboard
• Fig. 32 U.S. contraceptive market: Region market share analysis, 2025 & 2033
• Fig. 33 Southeast market, 2021 - 2033 (USD Billion)
• Fig. 34 West market, 2021 - 2033 (USD Billion)
• Fig. 35 Midwest market, 2021 - 2033 (USD Billion)
• Fig. 36 Northeast market, 2021 - 2033 (USD Billion)
• Fig. 37 Southwest market, 2021 - 2033 (USD Billion)
• Fig. 38 Company/competition categorization
• Fig. 39 Company market position analysis, 2025
• Fig. 40 U.S. contraceptive market: Strategy mapping